Dannce.ai November 2024 Pre-Seed Funding Round

DANNCE.AI has raised $2.6 million in funding to advance its AI-driven biomarker platform for neurological care. The technology enables objective, 3D analysis of patient movement through video, improving diagnostics and drug development for movement disorders. Originating at Harvard and Duke, the platform aims to replace subjective clinical evaluations with precise, automated assessments. It represents a shift toward data-driven insights in neurology and drug efficacy evaluations. Key investors include LDV Capital, Glasswing Ventures, and Merck Digital Sciences Studio.